Publication Name	World Journal of Gastroenterology
Manuscript ID	99549
Country	China

Received	2024-07-24 17:58
Peer-Review Started	2024-07-24 17:58
To Make the First Decision
Return for Revision	2024-09-25 06:46
Revised	2024-10-08 03:28
Second Decision	2024-11-25 02:34
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-25 06:10
Articles in Press	2024-11-25 06:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-27 00:37
Publish the Manuscript Online	2024-12-18 07:36

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Prospects of elafibranor in treating alcohol-associated liver diseases
Manuscript Source	Invited Manuscript
All Author List	Wei-Tong Cui, Hua-Ru Xue, Dian-Fang Wei, Xiao-Yu Feng and Kai Wang
ORCID	Author(s) ORCID Number Wei-Tong Cui http://orcid.org/0000-0001-9083-0494 Hua-Ru Xue http://orcid.org/0009-0001-1267-7217 Kai Wang http://orcid.org/0000-0002-3798-060X
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Shandong Province, China ZR2019PC053 Projects of Medical and Health Technology Development Program in Shandong Province, China 202202020837, 202301040472
Corresponding Author	Wei-Tong Cui, MD, Professor, School of Basic Medicine, Qilu Medical University, No. 1678 West Renmin Road, Zibo 255300, Shandong Province, China. klnr727@qlmu.edu.cn
Key Words	Elafibranor; Alcohol-associated liver diseases; Peroxisome proliferator-activated receptor; Lipid; Apoptosis; Steatosis; Inflammation; Fibrosis
Core Tip	Elafibranor is an oral dual peroxisome proliferator-activated receptor α/δ agonist that has demonstrated efficacy in improving hepatic steatosis and inhibiting inflammation and fibrosis associated with nonalcoholic liver diseases. Alcohol-related liver disease (ALD), resulting from excessive alcohol consumption, also presents symptoms such as hepatic steatosis, inflammation, and fibrosis. However, the effectiveness of elafibranor in treating ALD remains unclear. A recent study by Koizumi et al revealed that elafibranor significantly reduced hepatic steatosis, apoptosis, and fibrosis in a mouse model of ALD. Despite the potential of elafibranor for ALD treatment appears promising, further experimental investigations and clinical trials are warranted.
Publish Date	2024-12-18 07:36
Citation	<p>Cui WT, Xue HR, Wei DF, Feng XY, Wang K. Prospects of elafibranor in treating alcohol-associated liver diseases. <i>World J Gastroenterol</i> 2025; 31(2): 99549</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i2/99549.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i2.99549

Full Article (PDF)	WJG-31-99549-with-cover.pdf
Manuscript File	99549_Auto_Edited_100008.docx
Answering Reviewers	99549-answering-reviewers.pdf
Audio Core Tip	99549-audio.mp3
Conflict-of-Interest Disclosure Form	99549-conflict-of-interest-statement.pdf
Copyright License Agreement	99549-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	99549-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	99549-non-native-speakers.pdf
Peer-review Report	99549-peer-reviews.pdf
Scientific Misconduct Check	99549-scientific-misconduct-check.png
Scientific Editor Work List	99549-scientific-editor-work-list.pdf
CrossCheck Report	99549-crosscheck-report.pdf